Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Inventory: 2018-2025

Historic Inventory for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $828,053.

  • China SXT Pharmaceuticals' Inventory fell 13.36% to $751,346 in Q3 2025 from the same period last year, while for Sep 2025 it was $751,346, marking a year-over-year decrease of 13.36%. This contributed to the annual value of $828,053 for FY2025, which is 4.18% up from last year.
  • As of FY2025, China SXT Pharmaceuticals' Inventory stood at $828,053, which was up 4.18% from $794,855 recorded in FY2024.
  • China SXT Pharmaceuticals' 5-year Inventory high stood at $1.0 million for FY2022, and its period low was $531,254 during FY2023.
  • Over the past 3 years, China SXT Pharmaceuticals' median Inventory value was $794,855 (recorded in 2024), while the average stood at $718,054.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Inventory plummeted by 47.79% in 2023, and later soared by 49.62% in 2024.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Inventory stood at $859,696 in 2021, then increased by 18.36% to $1.0 million in 2022, then plummeted by 47.79% to $531,254 in 2023, then soared by 49.62% to $794,855 in 2024, then rose by 4.18% to $828,053 in 2025.